Spyre Therapeutics, Inc. (SYRE) Institutional Ownership

Ownership Summary

Spyre Therapeutics, Inc. (NASDAQ:SYRE) currently has 3 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in Spyre Therapeutics moved to 0.1% in December 2025, a shift down from the 87.8% reported for September 2025.
• The company experienced a 105.02% quarterly change in institutional shares held, alongside a decrease of 97.69% in total owners annually.
• A review of institutional activity for Spyre Therapeutics shows 2 of 3 filers increasing their positions, while 0 reduced their stake, and 1 remained unchanged.
• The total number of shares held by institutions in Spyre Therapeutics increased to 45.81K as of December 2025, a net change of up by 23.46K shares quarter on quarter, and down 59.76Mn shares year over year.
• SG Americas Securities, LLC's holding of 23.34K shares as of December 31, 2025 makes it the primary institutional investor in Spyre Therapeutics, owning 0.03% of the stock.
• Among the most significant buyers of Spyre Therapeutics during December 2025 were SG Americas Securities, LLC (23.34K), GAMMA Investing LLC (122).
• The top 3 institutional holders of Spyre Therapeutics for the quarter ending December 2025 included SG Americas Securities, LLC (23.34K), Assenagon Asset Management S.A. (22.14K), GAMMA Investing LLC (330).